Utilisation and variation in multimodality treatment for resected stage II–IIIA non-small cell lung cancer in England: a population-based cohort study

Authors:

Abstract
Background Systemic anti-cancer therapy (SACT) combined with surgical resection has become recommended practice for patients with resectable stage II–IIIA non-small cell lung cancer (NSCLC) who can tolerate SACT. This study examined how practice in England has responded to the changing evidence base. Methods We conducted a population-based cohort study using linked cancer registration, Hospital Episode Statistics, and Systemic Anti-Cancer Therapy datasets. The cohort included adults undergoing surgical resection for stage II–IIIA NSCLC between 2018 and 2023. Multimodality treatment was defined as surgery combined with SACT. Multivariable logistic regression was used to identify factors associated with treatment receipt; variation in treatment patterns was assessed by Cancer Alliance. Results Among 11,360 surgically treated patients, 6,103 (53.7%) received multimodality treatment. Most multimodality treatment combined surgery and adjuvant therapy (91.1%); but there was a small shift to greater use of neoadjuvant therapy in 2023. Greater use of multimodality treatment was associated with stage IIIA than stage II disease (65.0% vs 46.6%), younger age, better performance status, and lower frailty. There was persistent variation across Cancer Alliances, with case-mix-adjusted treatment rates ranging from approximately 49% to 61%. Conclusions In England, use of multimodality treatment for resected stage II–IIIA NSCLC has increased but remains incomplete and varies geographically. Treatment delivery was associated with patient fitness, tumour stage, and socioeconomic deprivation, but these factors did not explain regional variation, suggesting opportunities to improve equitable delivery of multimodality care in routine practice.